Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.78 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203279 | 0.92 | HTR6 (0.76) | HTR6HTR2AHTR2CKCNH2FEN1 | |
| SCHEMBL3320365 | 0.90 | HTR6 (0.64) | HTR6THRBRXFP1KCNH2 | |
| SCHEMBL5201434 | 0.88 | HTR6 (0.72) | HTR6 | |
| SCHEMBL1136470 | 0.88 | HTR6 (1.00) | HTR6 | |
| SCHEMBL1136509 | 0.88 | HTR6 (1.00) | HTR6HTR2AHTR2C | |
| SCHEMBL5205205 | 0.86 | HTR6 (0.66) | HTR6KCNH2 | |
| SCHEMBL6588061 | 0.84 | HTR6 (0.68) | HTR6FEN1 | |
| SCHEMBL5200503 | 0.82 | HTR6 (0.73) | HTR6HTR2AHTR2C | |
| SCHEMBL5203694 | 0.80 | HTR6 (0.85) | HTR6 | |
| SCHEMBL6587972 | 0.78 | HTR6 (0.82) | HTR6THRBHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101031338-B | Compositions and methods for treating cognitive disorders | HOFFMANN LA ROCHE | 2013-01-02 | — | — | CN | claimed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| CN-101031338-A | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (CH) | 2007-09-05 | — | — | CN | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| EP-1401813-B1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | claimed |
| CN-1257892-C | New indole derivatives with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| CN-1527816-A | Novel indole derivatives having 5-HT 6 receptor affinity | - | 2004-09-08 | — | — | CN | claimed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | claimed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | claimed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | claimed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | claimed |
| CN-101031338-B | Compositions and methods for treating cognitive disorders | HOFFMANN LA ROCHE | 2013-01-02 | — | — | CN | disclosed |
| CN-102114244-A | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2011-07-06 | — | — | CN | disclosed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-6787535-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PARKINSON'S DISEASE, HUNTINGTON'S DISEASE; PSYCOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-07 | — | — | US | disclosed |
| EP-1401813-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC | 2003-04-17 | — | — | US | disclosed |
| WO-2002098857-A1 | NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885THRB 597/4885RXFP1 1495/4885 |
| US-20030073700-A1 | New indole derivatives with 5HT6 receptor affinity | HTR6, HTR5A, HTR7 | HTR6 1/4885THRB 343/4885RXFP1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.